Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia
March 2001
Pfizer will soon market Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia.
Geodon will be widely used because it appears to cause less weight gain than other atypicals...Zyprexa, Seroquel, or Risperdal.
This is important. Weight gain is a common reason why patients discontinue therapy...and it increases the risk of developing diabetes and heart disease.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote